Medroxyprogesterone acetate - direct healthcare professional communication (DHPC)

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Medroxyprogesterone-containing medicines: Risk of meningioma and measures to minimise this risk

Key facts

• Active substance:
  medroxyprogesterone acetate
• Regulatory outcome:
  Variation
• DHPC type:
  Safety signal
• Dissemination date:
  03/10/2024
• Related medicines:
  Medroxyprogesterone-containing medicines